Clinical Trial Update: F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating F-18 16 alpha-fluoroestradiol PET to predict response to first-line hormone therapy in patients with stage IV estrogen recepto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Progesterone Receptor-negative Breast Cancer
• Progesterone Receptor-positive Breast Cancer

Drugs mentioned

• F-18 16 alpha-fluoroestradiol (fluoroestradiol labeled with Fluorine-18)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-12-25